The types and durations of antiplatelet drugs for symptomatic vertebrobasilar artery stenosis: a retrospective study
BackgroundPatients with symptomatic vertebrobasilar artery stenosis not only experience a first stroke event, but also have a high risk of recurrent stroke. Even though interventional techniques have been widely used in the treatment of cerebral infarction, the therapeutic efficacy for symptomatic v...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-04-01
|
| Series: | Frontiers in Neurology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2025.1553459/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850262480702406656 |
|---|---|
| author | Xi Liu Guanghong Zhong Hongli Gu Yangchun Wen Xiaojing Zhong Jia Zhang Ying Xie |
| author_facet | Xi Liu Guanghong Zhong Hongli Gu Yangchun Wen Xiaojing Zhong Jia Zhang Ying Xie |
| author_sort | Xi Liu |
| collection | DOAJ |
| description | BackgroundPatients with symptomatic vertebrobasilar artery stenosis not only experience a first stroke event, but also have a high risk of recurrent stroke. Even though interventional techniques have been widely used in the treatment of cerebral infarction, the therapeutic efficacy for symptomatic vertebrobasilar artery stenosis patients are not superior to that achieved with simple drug therapy. However, the optimal choice of drugs and the duration of their use in a pure drug regimen remain unclear.MethodsThis retrospective study analyzed data from Heyuan People’s Hospital (2021–2023) on patients with vertebrobasilar artery stenosis. Patients were grouped by treatment duration (30/90 days ticagrelor vs. 90 days clopidogrel), all receiving aspirin. Outcomes included ischemic events, bleeding, and complications. SPSS version 22.0 was employed for statistical analysis.ResultsThis study included 217 patients with symptomatic vertebrobasilar artery stenosis. Clinical features and outcomes of efficacy and safety analyses were conducted. No significant differences in baseline data or safety outcomes were found. However, a significant difference in endpoint events was observed within 90 days for specific subgroups of symptomatic intracranial vertebrobasilar artery stenosis and CYP2C19 gene deletion.ConclusionFor patients with symptomatic vertebrobasilar artery stenosis, the ticagrelor plus aspirin regimen may provide an alternative therapeutic option to the aspirin plus clopidogrel bisulfate regimen. Furthermore, this regimen may represent a favored treatment choice for specific patient subpopulations. |
| format | Article |
| id | doaj-art-8ec409aab6c2423b9698409d769e6cfb |
| institution | OA Journals |
| issn | 1664-2295 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neurology |
| spelling | doaj-art-8ec409aab6c2423b9698409d769e6cfb2025-08-20T01:55:11ZengFrontiers Media S.A.Frontiers in Neurology1664-22952025-04-011610.3389/fneur.2025.15534591553459The types and durations of antiplatelet drugs for symptomatic vertebrobasilar artery stenosis: a retrospective studyXi Liu0Guanghong Zhong1Hongli Gu2Yangchun Wen3Xiaojing Zhong4Jia Zhang5Ying Xie6Department of Neurology, Heyuan Hospital of Traditional Chinese Medicine, Heyuan, ChinaDepartment of Neurology, Heyuan People’s Hospital, Heyuan, ChinaDepartment of Neurology, Heyuan People’s Hospital, Heyuan, ChinaDepartment of Neurology, Heyuan Hospital of Traditional Chinese Medicine, Heyuan, ChinaDepartment of Neurology, Heyuan People’s Hospital, Heyuan, ChinaDepartment of Neurology, Heyuan People’s Hospital, Heyuan, ChinaDepartment of Neurology, Heyuan People’s Hospital, Heyuan, ChinaBackgroundPatients with symptomatic vertebrobasilar artery stenosis not only experience a first stroke event, but also have a high risk of recurrent stroke. Even though interventional techniques have been widely used in the treatment of cerebral infarction, the therapeutic efficacy for symptomatic vertebrobasilar artery stenosis patients are not superior to that achieved with simple drug therapy. However, the optimal choice of drugs and the duration of their use in a pure drug regimen remain unclear.MethodsThis retrospective study analyzed data from Heyuan People’s Hospital (2021–2023) on patients with vertebrobasilar artery stenosis. Patients were grouped by treatment duration (30/90 days ticagrelor vs. 90 days clopidogrel), all receiving aspirin. Outcomes included ischemic events, bleeding, and complications. SPSS version 22.0 was employed for statistical analysis.ResultsThis study included 217 patients with symptomatic vertebrobasilar artery stenosis. Clinical features and outcomes of efficacy and safety analyses were conducted. No significant differences in baseline data or safety outcomes were found. However, a significant difference in endpoint events was observed within 90 days for specific subgroups of symptomatic intracranial vertebrobasilar artery stenosis and CYP2C19 gene deletion.ConclusionFor patients with symptomatic vertebrobasilar artery stenosis, the ticagrelor plus aspirin regimen may provide an alternative therapeutic option to the aspirin plus clopidogrel bisulfate regimen. Furthermore, this regimen may represent a favored treatment choice for specific patient subpopulations.https://www.frontiersin.org/articles/10.3389/fneur.2025.1553459/fullsymptomatic vertebrobasilar artery stenosisantiplatelet drugsCYP2C19 geneticagrelorclopidogrel |
| spellingShingle | Xi Liu Guanghong Zhong Hongli Gu Yangchun Wen Xiaojing Zhong Jia Zhang Ying Xie The types and durations of antiplatelet drugs for symptomatic vertebrobasilar artery stenosis: a retrospective study Frontiers in Neurology symptomatic vertebrobasilar artery stenosis antiplatelet drugs CYP2C19 gene ticagrelor clopidogrel |
| title | The types and durations of antiplatelet drugs for symptomatic vertebrobasilar artery stenosis: a retrospective study |
| title_full | The types and durations of antiplatelet drugs for symptomatic vertebrobasilar artery stenosis: a retrospective study |
| title_fullStr | The types and durations of antiplatelet drugs for symptomatic vertebrobasilar artery stenosis: a retrospective study |
| title_full_unstemmed | The types and durations of antiplatelet drugs for symptomatic vertebrobasilar artery stenosis: a retrospective study |
| title_short | The types and durations of antiplatelet drugs for symptomatic vertebrobasilar artery stenosis: a retrospective study |
| title_sort | types and durations of antiplatelet drugs for symptomatic vertebrobasilar artery stenosis a retrospective study |
| topic | symptomatic vertebrobasilar artery stenosis antiplatelet drugs CYP2C19 gene ticagrelor clopidogrel |
| url | https://www.frontiersin.org/articles/10.3389/fneur.2025.1553459/full |
| work_keys_str_mv | AT xiliu thetypesanddurationsofantiplateletdrugsforsymptomaticvertebrobasilararterystenosisaretrospectivestudy AT guanghongzhong thetypesanddurationsofantiplateletdrugsforsymptomaticvertebrobasilararterystenosisaretrospectivestudy AT hongligu thetypesanddurationsofantiplateletdrugsforsymptomaticvertebrobasilararterystenosisaretrospectivestudy AT yangchunwen thetypesanddurationsofantiplateletdrugsforsymptomaticvertebrobasilararterystenosisaretrospectivestudy AT xiaojingzhong thetypesanddurationsofantiplateletdrugsforsymptomaticvertebrobasilararterystenosisaretrospectivestudy AT jiazhang thetypesanddurationsofantiplateletdrugsforsymptomaticvertebrobasilararterystenosisaretrospectivestudy AT yingxie thetypesanddurationsofantiplateletdrugsforsymptomaticvertebrobasilararterystenosisaretrospectivestudy AT xiliu typesanddurationsofantiplateletdrugsforsymptomaticvertebrobasilararterystenosisaretrospectivestudy AT guanghongzhong typesanddurationsofantiplateletdrugsforsymptomaticvertebrobasilararterystenosisaretrospectivestudy AT hongligu typesanddurationsofantiplateletdrugsforsymptomaticvertebrobasilararterystenosisaretrospectivestudy AT yangchunwen typesanddurationsofantiplateletdrugsforsymptomaticvertebrobasilararterystenosisaretrospectivestudy AT xiaojingzhong typesanddurationsofantiplateletdrugsforsymptomaticvertebrobasilararterystenosisaretrospectivestudy AT jiazhang typesanddurationsofantiplateletdrugsforsymptomaticvertebrobasilararterystenosisaretrospectivestudy AT yingxie typesanddurationsofantiplateletdrugsforsymptomaticvertebrobasilararterystenosisaretrospectivestudy |